查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2070464

核子醫學市場規模、市場佔有率、成長率、全球產業分析、區域分析及未來預測（2026-2034）

Nuclear Medicine Market Size, Share, Growth, Global Industry Analysis, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 246 Pages | 商品交期: 2-3個工作天內

價格

核子醫學市場的成長要素

全球核子醫學市場正經歷強勁成長，這主要得益於放射性藥物在診斷影像和標靶治療日益廣泛的應用。 2025年，該市場規模為117.7億美元。預計到2026年，市場規模將成長至137.2億美元，反映了臨床應用的增加和同位素供應的改善。到2034年，市場規模預計將達到557.5億美元，2026年至2034年的複合年成長率（CAGR）為19.15%。

預計到2025年，北美將引領市場，佔52.67%的市場。這主要歸功於其先進的影像基礎設施、強大的放射性藥物生產能力​​以及PET和SPECT掃描的廣泛應用。

市場概況及範圍

核子醫學是利用放射性藥物診斷和治療癌症、心血管疾病和神經系統疾病等疾病的領域。這包括用於診斷的PET和SPECT成像，以及用於治療的標靶放射性核素療法。

由於慢性病盛行率上升、對早期精準診斷的需求不斷成長以及治療診斷學的日益普及，市場正在不斷擴大。放射性同位素生產、影像系統和人工智慧診斷技術的進步，進一步提高了臨床效率和治療效果。

市場促進因素

核子醫學市場的主要促進因素之一是放射性藥物在標靶治療中的應用日益廣泛。這些療法能夠將輻射直接輸送到病變細胞，同時最大限度地減少對健康組織的損傷，從而提高治療的準確性和患者的治療效果。

核准放射性配體療法的數量不斷增加，以及其在腫瘤學領域臨床應用範圍的不斷擴大，顯著推動了市場需求。此外，各公司對同位素生產、製造設施和全球分銷網路的投資，也提高了產品的供應能力。

市場限制因素

放射性藥物的高成本和不完善的報銷政策仍然是市場成長的主要障礙。核子醫學產品的生產、處理和分銷需要專門的基礎設施和嚴格的安全規程，這進一步增加了整體治療成本。

由於保險覆蓋範圍有限，醫院採用先進的診斷和治療方法進展緩慢，尤其是在新興市場，這限制了患者獲得這些先進治療的機會。

市場機遇

將人工智慧 (AI) 應用於放射性藥物研發和診斷成像工作流程，正在創造巨大的成長機會。人工智慧有助於標靶識別、治療方案最佳化和診斷準確性提升。

將診斷和治療相結合的「診療整合」治療診斷學的擴展，正在開闢新的臨床應用領域，尤其是在腫瘤學領域。在新興市場，醫療保健投資的增加和疾病負擔的加重，正在創造更多機會。

市場區隔分析

按類型分類，到2025年，診斷領域將佔市場主導地位，這主要得益於PET和SPECT影像技術在疾病檢測、分期和監測中的廣泛應用。治療領域預計將以25.74%的複合年成長率成長，這主要受放射性配體療法和標靶α療法日益普及的推動。

按應用領域分類，預計到2025年，腫瘤學將佔最大佔有率，這主要歸功於核醫學在癌症檢測和治療方案製定中發揮的關鍵作用。神經病學領域預計將以18.70%的複合年成長率成長，這得益於其在腦部疾病診斷方面的應用不斷擴展。

按最終用戶分類，醫院和診所由於擁有龐大的患者群體和先進的診斷成像基礎設施，預計將在2025年佔市場主導地位。此外，為滿足門診病人日益成長的診斷影像需求，診斷中心也迅速擴張。

區域趨勢

2025年，北美以62億美元的市場規模領先全球市場，其主導地位得益於積極的臨床應用和完善的先進放射性藥物基礎設施。預計到2026年，美國市場規模將達到68.1億美元。

在積極的研究和治療診斷學（醫療和診斷）應用擴展的推動下，預計到 2026 年，歐洲市場規模將達到 22.1 億美元。在中日印醫療基礎設施擴張的支持下，預計到 2026 年，亞太地區市場規模將達到 22.3 億美元。

預計到 2026 年，拉丁美洲的經濟規模將達到 6.9 億美元，而包括海灣合作理事會國家在內的中東和非洲地區的經濟規模預計將達到 3.1 億美元。

目錄

第1章：引言

第2章摘要整理

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第4章 主要考慮因素

  • 主要國家已安裝的PET/PET-CT掃描儀數量（2025年估計值）
  • 主要國家部署的伽馬攝影機數量（估計值到2025年）
  • PET/PET-CT掃描數量：依主要國家分類（2025年估計值）
  • 管道分析：按主要公司分類
  • GA-68需求概述
  • 放射性同位素產生器：現況與未來趨勢概述
  • 關鍵產業趨勢（企業合併、新產品發布等）
  • 新冠疫情對市場的影響
  • 監理概覽：依主要國家分類
  • 主要製造商和迴旋加速器概覽
  • 供應鏈分析：放射性同位素

第5章：全球核子醫學市場：分析、討論與預測（2021-2034 年）

  • 市場分析、洞察與預測：按類型
    • 診斷
      • 用於PET掃描的放射性藥物
      • 用於SPECT的放射性藥物
    • 治療
      • Ra-223
      • Sm-153
      • Lu-177
      • I-131
      • Y-90
      • 其他
  • 市場分析、洞察與預測：按應用領域分類。
    • 神經病學
    • 循環系統
    • 腫瘤學
    • 其他
  • 市場分析、洞察與預測：按最終用戶分類
    • 醫院和診所
    • 診斷中心
    • 其他
  • 市場分析、洞察與預測：按地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章：北美核子醫學市場：分析、討論與預測（2021-2034 年）

  • 國家
    • 美國
    • 加拿大

第7章：歐洲核子醫學市場：分析、探討與預測（2021-2034 年）

  • 國家
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪地那維亞
    • 其他歐洲國家

第8章：亞太地區核子醫學市場：分析、洞察與預測（2021-2034 年）

  • 國家
    • 中國
    • 日本
    • 印度
    • 東南亞
    • 澳洲
    • 其他亞太國家

第9章：拉丁美洲核子醫學市場：分析、討論與預測（2021-2034 年）

  • 國家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第10章：中東和非洲核子醫學市場：分析、討論和預測（2021-2034 年）

  • 國家
    • 波灣合作理事會（GCC）國家
    • 南非
    • 其他中東和非洲國家

第11章 競爭分析

  • 全球市佔率分析（2025 年）
  • 公司簡介
    • GE HealthCare
    • Lantheus Holdings, Inc.
    • Nordion（Canada）Inc.（Sotera Health）
    • Bracco
    • Curium
    • Bayer AG
    • Siemens Healthineers AG
    • Novartis AG
    • Jubilant Pharmova Limited
    • Cardinal Health
    • Norgine
    • DuchemBio, Co., Ltd.
Product Code: FBI101812

Growth Factors of nuclear medicine Market

The global nuclear medicine market is experiencing strong expansion driven by increasing adoption of radiopharmaceuticals for both diagnostic imaging and targeted therapy. In 2025, the market was valued at USD 11.77 billion. In 2026, it is projected to grow to USD 13.72 billion, reflecting rising clinical adoption and improved isotope availability. By 2034, the market is expected to reach USD 55.75 billion, growing at a CAGR of 19.15% during 2026-2034.

North America dominated the market in 2025 with a 52.67% share, supported by advanced imaging infrastructure, strong radiopharmaceutical manufacturing capacity, and high usage of PET and SPECT procedures.

Market Overview and Scope

Nuclear medicine involves the use of radiopharmaceuticals for diagnosing and treating diseases such as cancer, cardiovascular disorders, and neurological conditions. It includes PET and SPECT imaging for diagnostics and targeted radionuclide therapy for treatment.

The market is expanding due to rising prevalence of chronic diseases, increasing demand for early and precise diagnosis, and growing adoption of theranostics. Advancements in radioisotope production, imaging systems, and AI-supported diagnostics are further enhancing clinical efficiency and treatment outcomes.

Market Drivers

A key driver of the nuclear medicine market is the increasing use of radiopharmaceuticals in targeted therapy. These therapies allow radiation to directly target diseased cells while minimizing damage to healthy tissues, improving treatment precision and patient outcomes.

Growing approvals of radioligand therapies and expanding clinical applications in oncology are significantly boosting demand. Investments by companies in isotope production, manufacturing facilities, and global distribution networks are also improving product availability.

Market Restraints

High costs of radiopharmaceuticals and inadequate reimbursement policies remain major barriers to market growth. The production, handling, and delivery of nuclear medicine products require specialized infrastructure and strict safety protocols, increasing overall treatment costs.

Limited reimbursement coverage reduces hospital adoption and restricts patient access to advanced diagnostic and therapeutic procedures, particularly in emerging markets.

Market Opportunities

The integration of artificial intelligence into radiopharmaceutical development and imaging workflows is creating strong growth opportunities. AI helps improve target identification, optimize treatment planning, and enhance diagnostic accuracy.

Expansion of theranostics, which combines diagnosis and therapy, is also opening new clinical applications, especially in oncology. Emerging markets offer further opportunities due to rising healthcare investments and increasing disease burden.

Market Segmentation Analysis

By type, diagnostics dominated the market in 2025 due to widespread use of PET and SPECT imaging for disease detection, staging, and monitoring. Therapeutics is expected to grow at a CAGR of 25.74%, driven by increasing use of radioligand therapies and targeted alpha treatments.

By application, oncology accounted for the largest share in 2025 as nuclear medicine plays a critical role in cancer detection and treatment planning. Neurology is expected to grow at a CAGR of 18.70% due to increasing applications in brain disorder diagnosis.

By end user, hospitals and clinics dominated the market in 2025 due to high patient volumes and availability of advanced imaging infrastructure. Diagnostic centers are also expanding rapidly as outpatient imaging demand increases.

Regional Insights

North America led the global market in 2025 with USD 6.20 billion, maintaining its dominance due to strong clinical adoption and advanced radiopharmaceutical infrastructure. The U.S. market is projected at USD 6.81 billion in 2026.

Europe is expected to reach USD 2.21 billion in 2026, driven by strong research activity and expanding theranostic applications. Asia Pacific is projected at USD 2.23 billion in 2026, supported by healthcare infrastructure expansion in China, Japan, and India.

Latin America is expected to reach USD 0.69 billion in 2026, while the Middle East & Africa region, including GCC countries, is projected at USD 0.31 billion.

Competitive Landscape

The nuclear medicine market is semi-fragmented with key players including Novartis AG, Lantheus Holdings, Curium, Bracco, Siemens Healthineers, Bayer AG, and GE HealthCare. These companies are focusing on radiopharmaceutical expansion, acquisitions, and manufacturing capacity enhancement.

Strategic moves such as SHINE's acquisition of Lantheus' SPECT business and Novartis expanding radioligand manufacturing facilities highlight strong industry consolidation and growth momentum.

Conclusion

The global nuclear medicine market is projected to grow from USD 11.77 billion in 2025 to USD 13.72 billion in 2026 and reach USD 55.75 billion by 2034. Strong demand for precision diagnostics, increasing adoption of radiopharmaceutical therapies, and technological advancements in imaging and theranostics will continue to drive long-term market growth.

Segmentation By Type, Application, End User, and Region

By Type * Diagnostics

    • PET Radiopharmaceuticals
  • FDG-PET/18F
  • 68Ga
  • 68Cu
  • 11C
  • Others
    • SPECT Radiopharmaceuticals
  • Technetium-99m
  • Iodine-123
  • Xenon-133
  • Thallium-201
  • Others
  • Therapeutics
    • Ra-223
    • Sm-153
    • Lu-177
    • I-131
    • Y-90
    • Others

By Application * Neurology

  • Cardiology
  • Oncology
  • Others

By End-user * Hospitals & Clinics

  • Diagnostic Centers
  • Others

By Region * North America (By Type, Application, End User, and Country)

    • U.S.
    • Canada
  • Europe (By Type, Application, End User, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Type, Application, End User, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Type, Application, End User, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Type, Application, End User, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Installed Base of PET/PET CT Scanners (Estimated), By Key Countries, 2025
  • 4.2. Installed Base of Gamma Cameras (Estimated), By Key Countries, 2025
  • 4.3. PET/PET CT Procedure Volume (Estimated), By Key Countries, 2025
  • 4.4. Pipeline Analysis, By Key Players
  • 4.5. Overview: Ga-68 Demand
  • 4.6. Overview: Radioisotope Generators, Current & Future Trends
  • 4.7. Key Industry Developments (Mergers, Acquisitions, New Product Launches, etc.)
  • 4.8. Impact of COVID-19 on the Market
  • 4.9. Regulatory Overview: Key Countries/ Region
  • 4.10. Brief Profiles of Key Manufacturers, Cyclotrons
  • 4.11. Supply Chain Analysis: Radioisotopes

5. Global Nuclear Medicine Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Type
    • 5.1.1. Diagnostics
      • 5.1.1.1. PET Radiopharmaceuticals
        • 5.1.1.1.1. FDG-PET/18F
        • 5.1.1.1.2. 68Ga
        • 5.1.1.1.3. 68Cu
        • 5.1.1.1.4. 11C
        • 5.1.1.1.5. Others
      • 5.1.1.2. SPECT Radiopharmaceuticals
        • 5.1.1.2.1. Technetium-99m
        • 5.1.1.2.2. Iodine-123
        • 5.1.1.2.3. Xenon-133
        • 5.1.1.2.4. Thallium-201
        • 5.1.1.2.5. Others
    • 5.1.2. Therapeutics
      • 5.1.2.1. Ra-223
      • 5.1.2.2. Sm-153
      • 5.1.2.3. Lu-177
      • 5.1.2.4. I-131
      • 5.1.2.5. Y-90
      • 5.1.2.6. Others
  • 5.2. Market Analysis, Insights and Forecast - By Application
    • 5.2.1. Neurology
    • 5.2.2. Cardiology
    • 5.2.3. Oncology
    • 5.2.4. Others
  • 5.3. Market Analysis, Insights and Forecast - By End-user
    • 5.3.1. Hospitals & Clinics
    • 5.3.2. Diagnostic Centers
    • 5.3.3. Others
  • 5.4. Market Analysis, Insights and Forecast - Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Nuclear Medicine Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Type
    • 6.1.1. Diagnostics
      • 6.1.1.1. PET Radiopharmaceuticals
        • 6.1.1.1.1. FDG-PET/18F
        • 6.1.1.1.2. 68Ga
        • 6.1.1.1.3. 68Cu
        • 6.1.1.1.4. 11C
        • 6.1.1.1.5. Others
      • 6.1.1.2. SPECT Radiopharmaceuticals
        • 6.1.1.2.1. Technetium-99m
        • 6.1.1.2.2. Iodine-123
        • 6.1.1.2.3. Xenon-133
        • 6.1.1.2.4. Thallium-201
        • 6.1.1.2.5. Others
    • 6.1.2. Therapeutics
      • 6.1.2.1. Ra-223
      • 6.1.2.2. Sm-153
      • 6.1.2.3. Lu-177
      • 6.1.2.4. I-131
      • 6.1.2.5. Y-90
      • 6.1.2.6. Others
  • 6.2. Market Analysis, Insights and Forecast - By Application
    • 6.2.1. Neurology
    • 6.2.2. Cardiology
    • 6.2.3. Oncology
    • 6.2.4. Others
  • 6.3. Market Analysis, Insights and Forecast - By End-user
    • 6.3.1. Hospitals & Clinics
    • 6.3.2. Diagnostic Centers
    • 6.3.3. Others
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Nuclear Medicine Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Type
    • 7.1.1. Diagnostics
      • 7.1.1.1. PET Radiopharmaceuticals
        • 7.1.1.1.1. FDG-PET/18F
        • 7.1.1.1.2. 68Ga
        • 7.1.1.1.3. 68Cu
        • 7.1.1.1.4. 11C
        • 7.1.1.1.5. Others
      • 7.1.1.2. SPECT Radiopharmaceuticals
        • 7.1.1.2.1. Technetium-99m
        • 7.1.1.2.2. Iodine-123
        • 7.1.1.2.3. Xenon-133
        • 7.1.1.2.4. Thallium-201
        • 7.1.1.2.5. Others
    • 7.1.2. Therapeutics
      • 7.1.2.1. Ra-223
      • 7.1.2.2. Sm-153
      • 7.1.2.3. Lu-177
      • 7.1.2.4. I-131
      • 7.1.2.5. Y-90
      • 7.1.2.6. Others
  • 7.2. Market Analysis, Insights and Forecast - By Application
    • 7.2.1. Neurology
    • 7.2.2. Cardiology
    • 7.2.3. Oncology
    • 7.2.4. Others
  • 7.3. Market Analysis, Insights and Forecast - By End-user
    • 7.3.1. Hospitals & Clinics
    • 7.3.2. Diagnostic Centers
    • 7.3.3. Others
  • 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.4.1. U.K.
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Italy
    • 7.4.5. Spain
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific Nuclear Medicine Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Type
    • 8.1.1. Diagnostics
      • 8.1.1.1. PET Radiopharmaceuticals
        • 8.1.1.1.1. FDG-PET/18F
        • 8.1.1.1.2. 68Ga
        • 8.1.1.1.3. 68Cu
        • 8.1.1.1.4. 11C
        • 8.1.1.1.5. Others
      • 8.1.1.2. SPECT Radiopharmaceuticals
        • 8.1.1.2.1. Technetium-99m
        • 8.1.1.2.2. Iodine-123
        • 8.1.1.2.3. Xenon-133
        • 8.1.1.2.4. Thallium-201
        • 8.1.1.2.5. Others
    • 8.1.2. Therapeutics
      • 8.1.2.1. Ra-223
      • 8.1.2.2. Sm-153
      • 8.1.2.3. Lu-177
      • 8.1.2.4. I-131
      • 8.1.2.5. Y-90
      • 8.1.2.6. Others
  • 8.2. Market Analysis, Insights and Forecast - By Application
    • 8.2.1. Neurology
    • 8.2.2. Cardiology
    • 8.2.3. Oncology
    • 8.2.4. Others
  • 8.3. Market Analysis, Insights and Forecast - By End-user
    • 8.3.1. Hospitals & Clinics
    • 8.3.2. Diagnostic Centers
    • 8.3.3. Others
  • 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.4.1. China
    • 8.4.2. Japan
    • 8.4.3. India
    • 8.4.4. Southeast Asia
    • 8.4.5. Australia
    • 8.4.6. Rest of Asia Pacific

9. Latin America Nuclear Medicine Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Type
    • 9.1.1. Diagnostics
      • 9.1.1.1. PET Radiopharmaceuticals
        • 9.1.1.1.1. FDG-PET/18F
        • 9.1.1.1.2. 68Ga
        • 9.1.1.1.3. 68Cu
        • 9.1.1.1.4. 11C
        • 9.1.1.1.5. Others
      • 9.1.1.2. SPECT Radiopharmaceuticals
        • 9.1.1.2.1. Technetium-99m
        • 9.1.1.2.2. Iodine-123
        • 9.1.1.2.3. Xenon-133
        • 9.1.1.2.4. Thallium-201
        • 9.1.1.2.5. Others
    • 9.1.2. Therapeutics
      • 9.1.2.1. Ra-223
      • 9.1.2.2. Sm-153
      • 9.1.2.3. Lu-177
      • 9.1.2.4. I-131
      • 9.1.2.5. Y-90
      • 9.1.2.6. Others
  • 9.2. Market Analysis, Insights and Forecast - By Application
    • 9.2.1. Neurology
    • 9.2.2. Cardiology
    • 9.2.3. Oncology
    • 9.2.4. Others
  • 9.3. Market Analysis, Insights and Forecast - By End-user
    • 9.3.1. Hospitals & Clinics
    • 9.3.2. Diagnostic Centers
    • 9.3.3. Others
  • 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Rest of Latin America

10. Middle East & Africa Nuclear Medicine Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Type
    • 10.1.1. Diagnostics
      • 10.1.1.1. PET Radiopharmaceuticals
        • 10.1.1.1.1. FDG-PET/18F
        • 10.1.1.1.2. 68Ga
        • 10.1.1.1.3. 68Cu
        • 10.1.1.1.4. 11C
        • 10.1.1.1.5. Others
      • 10.1.1.2. SPECT Radiopharmaceuticals
        • 10.1.1.2.1. Technetium-99m
        • 10.1.1.2.2. Iodine-123
        • 10.1.1.2.3. Xenon-133
        • 10.1.1.2.4. Thallium-201
        • 10.1.1.2.5. Others
    • 10.1.2. Therapeutics
      • 10.1.2.1. Ra-223
      • 10.1.2.2. Sm-153
      • 10.1.2.3. Lu-177
      • 10.1.2.4. I-131
      • 10.1.2.5. Y-90
      • 10.1.2.6. Others
  • 10.2. Market Analysis, Insights and Forecast - By Application
    • 10.2.1. Neurology
    • 10.2.2. Cardiology
    • 10.2.3. Oncology
    • 10.2.4. Others
  • 10.3. Market Analysis, Insights and Forecast - By End-user
    • 10.3.1. Hospitals & Clinics
    • 10.3.2. Diagnostic Centers
    • 10.3.3. Others
  • 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.4.1. GCC
    • 10.4.2. South Africa
    • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. GE HealthCare
    • 11.2.2. Lantheus Holdings, Inc.
    • 11.2.3. Nordion (Canada) Inc. (Sotera Health)
    • 11.2.4. Bracco
    • 11.2.5. Curium
    • 11.2.6. Bayer AG
    • 11.2.7. Siemens Healthineers AG
    • 11.2.8. Novartis AG
    • 11.2.9. Jubilant Pharmova Limited
    • 11.2.10. Cardinal Health
    • 11.2.11. Norgine
    • 11.2.12. DuchemBio, Co., Ltd.

List of Tables

  • Figure 1: Global Nuclear Medicine Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Nuclear Medicine Market Value Share (%), by Type, 2025 & 2034
  • Figure 3: Global Nuclear Medicine Market Value Share (%), by Application, 2025 & 2034
  • Figure 4: Global Nuclear Medicine Market Value Share (%), by End-user, 2025 & 2034
  • Figure 5: Global Nuclear Medicine Market Value Share (%), by Region, 2025 & 2034
  • Figure 6: North America Nuclear Medicine Market Value (USD billion), by Type, 2025 & 2034
  • Figure 7: North America Nuclear Medicine Market Value Share (%), by Type, 2025
  • Figure 8: North America Nuclear Medicine Market Value (USD billion), by Application, 2025 & 2034
  • Figure 9: North America Nuclear Medicine Market Value Share (%), by Application, 2025
  • Figure 10: North America Nuclear Medicine Market Value (USD billion), by End-user, 2025 & 2034
  • Figure 11: North America Nuclear Medicine Market Value Share (%), by End-user, 2025
  • Figure 12: North America Nuclear Medicine Market Value (USD billion), by Country, 2025 & 2034
  • Figure 13: North America Nuclear Medicine Market Value Share (%), by Country, 2025
  • Figure 14: Europe Nuclear Medicine Market Value (USD billion), by Type, 2025 & 2034
  • Figure 15: Europe Nuclear Medicine Market Value Share (%), by Type, 2025
  • Figure 16: Europe Nuclear Medicine Market Value (USD billion), by Application, 2025 & 2034
  • Figure 17: Europe Nuclear Medicine Market Value Share (%), by Application, 2025
  • Figure 18: Europe Nuclear Medicine Market Value (USD billion), by End-user, 2025 & 2034
  • Figure 19: Europe Nuclear Medicine Market Value Share (%), by End-user, 2025
  • Figure 20: Europe Nuclear Medicine Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 21: Europe Nuclear Medicine Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 22: Asia Pacific Nuclear Medicine Market Value (USD billion), by Type, 2025 & 2034
  • Figure 23: Asia Pacific Nuclear Medicine Market Value Share (%), by Type, 2025
  • Figure 24: Asia Pacific Nuclear Medicine Market Value (USD billion), by Application, 2025 & 2034
  • Figure 25: Asia Pacific Nuclear Medicine Market Value Share (%), by Application, 2025
  • Figure 26: Asia Pacific Nuclear Medicine Market Value (USD billion), by End-user, 2025 & 2034
  • Figure 27: Asia Pacific Nuclear Medicine Market Value Share (%), by End-user, 2025
  • Figure 28: Asia Pacific Nuclear Medicine Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 29: Asia Pacific Nuclear Medicine Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 30: Latin America Nuclear Medicine Market Value (USD billion), by Type, 2025 & 2034
  • Figure 31: Latin America Nuclear Medicine Market Value Share (%), by Type, 2025
  • Figure 32: Latin America Nuclear Medicine Market Value (USD billion), by Application, 2025 & 2034
  • Figure 33: Latin America Nuclear Medicine Market Value Share (%), by Application, 2025
  • Figure 34: Latin America Nuclear Medicine Market Value (USD billion), by End-user, 2025 & 2034
  • Figure 35: Latin America Nuclear Medicine Market Value Share (%), by End-user, 2025
  • Figure 36: Latin America Nuclear Medicine Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 37: Latin America Nuclear Medicine Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 38: Middle East & Africa Nuclear Medicine Market Value (USD billion), by Type, 2025 & 2034
  • Figure 39: Middle East & Africa Nuclear Medicine Market Value Share (%), by Type, 2025
  • Figure 40: Middle East & Africa Nuclear Medicine Market Value (USD billion), by Application, 2025 & 2034
  • Figure 41: Middle East & Africa Nuclear Medicine Market Value Share (%), by Application, 2025
  • Figure 42: Middle East & Africa Nuclear Medicine Market Value (USD billion), by End-user, 2025 & 2034
  • Figure 43: Middle East & Africa Nuclear Medicine Market Value Share (%), by End-user, 2025
  • Figure 44: Middle East & Africa Nuclear Medicine Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 45: Middle East & Africa Nuclear Medicine Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 46: Global Nuclear Medicine Market Share (%), by Company, 2025